Skip to content
Triangle logo TriangleGet started
← Study library

NCT00822120 · CITED IN SOURCE DOCUMENTS

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2022-08-18

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. G-CSF may help lessen the side effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F 18-PET/CT imaging, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing response to combination chemotherapy and allow doctors to plan better additional further treatment in treating patients with stage III or stage IV Hodgkin lymphoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.

→

outcome · POSTED

Percentage of HIV-negative Patients Who Are PET-positive After 2 Cycles of ABVD With 2-year PFS

→

outcome · POSTED

Percentage of HIV-negative Patients With 2-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging

→

outcome · POSTED

Complete and Partial Response Rates for HIV-negative Patients Treated With Response- Adapted Therapy Based on FDG-PET Imaging After 2 Cycles of ABVD

→

outcome · POSTED

Number of HIV-negative Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug

→

outcome · POSTED

Percentage of HIV-positive Patients With 2-year Progression-free Survival (PFS) Treated With Initial 2 Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.

→

outcome · POSTED

Percentage of HIV-positive Patients With 5-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging.

→

outcome · POSTED

Complete and Partial Response Rates for HIV-positive Patients Treated With Response-Adapted Therapy Based on FDG-PET Imaging After 2 Cycles of ABVD

→

outcome · POSTED

Number of HIV-positive Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted) * Previously untreated stage III or IV disease * No nodular lymphocyte predominant disease * Bidimensionally measurable disease * Adequate biopsy samples from original diagnostic specimen must be available for pathologic review * Tissue obtained from core biopsies allowed * No tissue obtained from needle aspirations or cytologies * Must have known HIV status * No multi-drug resistant HIV infection, CD4 counts \< 150/μL, or other concurrent AIDS-defining conditions in HIV-positive patients * HIV-positive patients with CD4 counts ≥ 150/μL at the time of enrollment OR documented CD4 count \> 250/μL at any time within 8 months prior to HL diagnosis allowed * Must have undergone unilateral or bilateral bone marrow biopsy within the past 42 days * Must have a diagnostic quality CT scan of the chest/abdomen and pelvis AND baseline FDG-PET scan within the past 28 days * Combined PET/CT scans required * No older "stand-alone" FDG-PET scans * No low-resolution "localization" CT scans as part of a combined PET/CT scans PATIENT CHARACTERISTICS: * Zubrod performance status 0-2 * Serum erythrocyte sedimentation rate, lactate dehydrogenase (LDH), hemoglobin, albumin, white blood cell count (WBC), and lymphocytes measured within the past 28 days * Serum estradiol (women only), testosterone (men only), follicle stimulating hormone (FSH) and luteinizing hormone (LH) (both men and women) levels must be drawn within 60 days prior to registration * Not pregnant or nursing * Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy * No significant cardiac abnormalities as assessed by multiple gated acquisition scan (MUGA) or ECHO AND cardiac ejection fraction ≥ 45% in patients with a history of hypertension or cardiac symptoms * Hepatitis B-negative (i.e., hepatitis B surface antigen-negative or anti-hepatitis B core antigen-negative) * Patients immune to or immunized against hepatitis B (i.e., anti-hepatitis B surface antibody-positive) are eligible * Hepatitis C-negative (i.e., anti-hepatitis C antibody-negative) * No significant lung disease with abnormal lung function tests (i.e., diffusing capacity of lung for carbon monoxide (DLCO) \> 25% below predicted after correction for hemoglobin) unless attributable to lymphoma * No requirement for continuous supplemental oxygen therapy * No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior chemotherapy, radiotherapy, or antibody therapy for lymphoma * No prior solid organ transplantation
healthy Volunteers
false
maximum Age
60 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
Treatment arms and interventions
arm Groups
  1. description
    Etoposide 100 mg/m2 IV Days 1, 2, 3 Dox 25 mg/m2 IV Day 1 Cyclo 650mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 Q 21 Days x 6 cycles
    intervention Names
    1. Biological: bleomycin sulfate
    2. Drug: BEACOPP regimen
    3. Drug: cyclophosphamide
    4. Drug: doxorubicin hydrochloride
    5. Drug: etoposide
    6. Drug: prednisone
    7. Drug: procarbazine hydrochloride
    8. Drug: vincristine sulfate
    label
    HIV Positive, PET Positive: BEACOPP standard
    type
    EXPERIMENTAL
  2. description
    Etoposide 200 mg/m2 IV Days 1, 2, 3 Dox 35 mg/m2 IV Day 1 Cyclo 1,250 mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 G-CSF 5mcg/kg/day SQ Days 8-14 Q 21 Days x 6 cycles
    intervention Names
    1. Biological: bleomycin sulfate
    2. Biological: filgrastim
    3. Drug: BEACOPP regimen
    4. Drug: cyclophosphamide
    5. Drug: doxorubicin hydrochloride
    6. Drug: etoposide
    7. Drug: prednisone
    8. Drug: procarbazine hydrochloride
    9. Drug: vincristine sulfate
    label
    HIV Negative, PET Positive: BEACOPP escalated
    type
    EXPERIMENTAL
  3. description
    Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
    intervention Names
    1. Biological: bleomycin sulfate
    2. Drug: ABVD regimen
    3. Drug: dacarbazine
    4. Drug: doxorubicin hydrochloride
    5. Drug: vinblastine sulfate
    label
    HIV Positive, PET Negative: ABVD
    type
    ACTIVE_COMPARATOR
  4. description
    Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
    intervention Names
    1. Biological: bleomycin sulfate
    2. Drug: ABVD regimen
    3. Drug: dacarbazine
    4. Drug: doxorubicin hydrochloride
    5. Drug: vinblastine sulfate
    label
    HIV Negative, PET Negative: ABVD
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. HIV Negative, PET Negative: ABVD
    2. HIV Negative, PET Positive: BEACOPP escalated
    3. HIV Positive, PET Negative: ABVD
    4. HIV Positive, PET Positive: BEACOPP standard
    name
    bleomycin sulfate
    type
    BIOLOGICAL
  2. arm Group Labels
    1. HIV Negative, PET Positive: BEACOPP escalated
    name
    filgrastim
    type
    BIOLOGICAL
  3. arm Group Labels
    1. HIV Negative, PET Negative: ABVD
    2. HIV Positive, PET Negative: ABVD
    name
    ABVD regimen
    type
    DRUG
  4. arm Group Labels
    1. HIV Negative, PET Positive: BEACOPP escalated
    2. HIV Positive, PET Positive: BEACOPP standard
    name
    BEACOPP regimen
    type
    DRUG
  5. arm Group Labels
    1. HIV Negative, PET Positive: BEACOPP escalated
    2. HIV Positive, PET Positive: BEACOPP standard
    name
    cyclophosphamide
    type
    DRUG
  6. arm Group Labels
    1. HIV Negative, PET Negative: ABVD
    2. HIV Positive, PET Negative: ABVD
    name
    dacarbazine
    type
    DRUG
  7. arm Group Labels
    1. HIV Negative, PET Negative: ABVD
    2. HIV Negative, PET Positive: BEACOPP escalated
    3. HIV Positive, PET Negative: ABVD
    4. HIV Positive, PET Positive: BEACOPP standard
    name
    doxorubicin hydrochloride
    type
    DRUG
  8. arm Group Labels
    1. HIV Negative, PET Positive: BEACOPP escalated
    2. HIV Positive, PET Positive: BEACOPP standard
    name
    etoposide
    type
    DRUG
  9. arm Group Labels
    1. HIV Negative, PET Positive: BEACOPP escalated
    2. HIV Positive, PET Positive: BEACOPP standard
    name
    prednisone
    type
    DRUG
  10. arm Group Labels
    1. HIV Negative, PET Positive: BEACOPP escalated
    2. HIV Positive, PET Positive: BEACOPP standard
    name
    procarbazine hydrochloride
    type
    DRUG
  11. arm Group Labels
    1. HIV Negative, PET Negative: ABVD
    2. HIV Positive, PET Negative: ABVD
    name
    vinblastine sulfate
    type
    DRUG
  12. arm Group Labels
    1. HIV Negative, PET Positive: BEACOPP escalated
    2. HIV Positive, PET Positive: BEACOPP standard
    name
    vincristine sulfate
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
371
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or \>= 50% increase in greatest transverse diameter (GTD) of any nodal \> 1 cm in shortest axis, or \>= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is \> 1.5 cm or if both long and short axes are \> 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. Progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact.
    measure
    Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.
    time Frame
    2 years
  2. description
    Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or \>= 50% increase in greatest transverse diameter (GTD) of any nodal \> 1 cm in shortest axis, or \>= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is \> 1.5 cm or if both long and short axes are \> 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. Progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact.
    measure
    Percentage of HIV-negative Patients Who Are PET-positive After 2 Cycles of ABVD With 2-year PFS
    time Frame
    2 years
secondary Outcomes
  1. description
    Measured from date of registration to date of death due to any cause. Patients last known to be alive and are censored at date of last contact.
    measure
    Percentage of HIV-negative Patients With 2-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging
    time Frame
    2 years
  2. description
    Complete Response (CR) is a complete disappearance of all disease with the exception of the following. If no PET scan or when the PET scan was positive before therapy, a post-treatment residual mass of any size is permitted if it is PET negative. If the PET scan was negative before therapy, all nodal masses at baseline must have regressed. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow (BM) must be negative if positive at baseline. Normalization of markers. Partial Response (PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. If PET scan or when the PET scan was positive before therapy, PET should be positive in at least one previously involved site.
    measure
    Complete and Partial Response Rates for HIV-negative Patients Treated With Response- Adapted Therapy Based on FDG-PET Imaging After 2 Cycles of ABVD
    time Frame
    7 months after registration
  3. description
    Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.
    measure
    Number of HIV-negative Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
    time Frame
    Up to 1 year
  4. description
    Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or \>= 50% increase in greatest transverse diameter (GTD) of any nodal \> 1 cm in shortest axis, or \>= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is \>1.5 cm or if both long and short axes are \> 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact.
    measure
    Percentage of HIV-positive Patients With 2-year Progression-free Survival (PFS) Treated With Initial 2 Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.
    time Frame
    2 years
  5. description
    Measured from date of registration to date of death due to any cause. Patients last known to be alive and are censored at date of last contact.
    measure
    Percentage of HIV-positive Patients With 5-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging.
    time Frame
    5 years
  6. description
    Complete Response (CR) is a complete disappearance of all disease with the exception of the following. If no PET scan or when the PET scan was positive before therapy, a post-treatment residual mass of any size is permitted if it is PET negative. If the PET scan was negative before therapy, all nodal masses at baseline must have regressed. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow (BM) must be negative if positive at baseline. Normalization of markers. Partial Response (PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. If PET scan or when the PET scan was positive before therapy, PET should be positive in at least one previously involved site.
    measure
    Complete and Partial Response Rates for HIV-positive Patients Treated With Response-Adapted Therapy Based on FDG-PET Imaging After 2 Cycles of ABVD
    time Frame
    7 months after registration
  7. description
    Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.
    measure
    Number of HIV-positive Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
    time Frame
    Up to 1 year
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. G-CSF may help lessen the side effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F 18-PET/CT imaging, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing response to combination chemotherapy and allow doctors to plan better additional further treatment in treating patients with stage III or stage IV Hodgkin lymphoma.
detailed Description
OBJECTIVES: Primary * To estimate the 2-year progression-free survival (PFS) of HIV-negative patients with stage III-IV Hodgkin lymphoma treated with response-adapted therapy based on fludeoxyglucose F 18 (FDG)-PET imaging after 2 courses of doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine (ABVD). * To estimate the 2-year PFS of patients who are PET-positive after treatment with 2 courses of ABVD and an escalated dose regimen comprising cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, bleomycin, procarbazine hydrochloride, and prednisone (BEACOPP). Secondary * To estimate the 2-year overall survival (OS) of patients treated with these regimens. * To estimate the response rate (i.e., complete and partial responses) in patients treated with these regimens. * To evaluate the toxicity of these response-adapted regimens. * To document the feasibility of centralized, real-time review of FDG-PET imaging for U.S. cooperative group studies. * To prospectively evaluate the overall response rate, complete response rate, PFS, and OS of HIV-positive patients treated with these response-adapted regimens. OUTLINE: This is a multicenter study. All patients undergo baseline whole-body fludeoxyglucose F 18 (FDG)-PET/CT imaging before beginning chemotherapy. Patients then receive doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV (ABVD) on days 1 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Between days 22 and 25 of course 2, patients undergo a second FDG-PET/CT scan to assess response. Subsequent therapy is based on FDG-PET/CT scan results. Patients are stratified according to FDG-PET positivity (yes vs no). Patients who are FDG-PET-negative continue treatment with ABVD for up to 4 additional courses in the absence of disease progression or unacceptable toxicity. Patients who are FDG-PET-positive are then further stratified according to HIV positivity (yes or no) and receive 1 of the following treatment regimens: * Escalated-dose BEACOPP chemotherapy: HIV-negative patients receive escalated-dose BEACOPP chemotherapy comprising doxorubicin hydrochloride IV and cyclophosphamide IV on day 1, etoposide IV on days 1-3, oral procarbazine hydrochloride on days 1-7, oral prednisone on days 1-14, and bleomycin IV and vincristine IV on day 8. Patients receive filgrastim (G-CSF) subcutaneously on days 8-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. * Standard-dose BEACOPP chemotherapy: HIV-positive patients receive standard dose BEACOPP chemotherapy comprising doxorubicin hydrochloride IV and cyclophosphamide IV on day 1, etoposide IV on days 1-3, oral procarbazine hydrochloride on days 1-7, oral prednisone on days 1-14, and bleomycin IV and vincristine IV on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Six to eight weeks after completion of chemotherapy, patients undergo a post-treatment FDG-PET/CT scan. Some patients may undergo bone marrow biopsy at 1 month after the last course of chemotherapy. After completion of study treatment, patients are followed up periodically for 7 years.
Source references
references
  1. citation
    Kreuzberger N, Goldkuhle M, von Tresckow B, Kobe C, Sickinger MT, Monsef I, Skoetz N. Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. Cochrane Database Syst Rev. 2025 Mar 26;3(3):CD010533. doi: 10.1002/14651858.CD010533.pub3.
    pmid
    40135712
    type
    DERIVED
  2. citation
    Stephens DM, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019 Oct 10;134(15):1238-1246. doi: 10.1182/blood.2019000719.
    pmid
    31331918
    type
    DERIVED
  3. citation
    Hsi ED, Li H, Nixon AB, Schoder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019 Apr 18;133(16):1762-1765. doi: 10.1182/blood-2018-08-870915. Epub 2019 Feb 5.
    pmid
    30723079
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-6cf1cd845be891eadd85
      requested nct id
      NCT00822120
      primary nct id
      NCT00822120
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      b73d58cc901225655c1e0b5a529bfad102894e39e86f356aab4e49f88cd28ca1
      payload sha256
      12a552555568560b9a9d498f8237e3a6a3b7bd7a86f881d76f0af510f977918d
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-6cf1cd845be891eadd85
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00822120
      occurrences
      1. context exact
        tablish that switching to BEACOPP was superior to remaining on ABVD.</li></ul></div></li></ol></div></li><li>In a nonrandomized trial (<a href="/clinicaltrials/NCT00822120">SWOG S0816</a> [NCT00822120]), 336 patients with advanced HL received two cycles of ABVD and then were evaluated by PET scan.[<a href="#cit/section_7.27">27</
        end
        205561
        exact text
        NCT00822120
        start
        205550
      2. context exact
        COPP was superior to remaining on ABVD.</li></ul></div></li></ol></div></li><li>In a nonrandomized trial (<a href="/clinicaltrials/NCT00822120">SWOG S0816</a> [NCT00822120]), 336 patients with advanced HL received two cycles of ABVD and then were evaluated by PET scan.[<a href="#cit/section_7.27">27</a>] PET2&#8211;negative patie
        end
        205590
        exact text
        NCT00822120
        start
        205579
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/c88b4a702bd9661788.html
      source file sha256
      b73d58cc901225655c1e0b5a529bfad102894e39e86f356aab4e49f88cd28ca1
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:01.623846+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      9a6e61e7bcb841d8aee6690e948cea06b80b68c51413cf7a1eba5ed41d1a2a76
      source title
      Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: February 12, 2025
        datetime
        2025-02-12T12:00:00Z
        display
        February 12, 2025

    Preserved source evidence · Not medical advice